Cardiovascular Systems announces first patient enrolled in REACH PVI clinical study
Ngày 13/06/2019 07:58 | Lượt xem: 1474

Cardiovascular Systems recently announced that the first patient has been enrolled in the REACH PVI study. The purpose of this study is to prospectively evaluate acute clinical outcomes of orbital atherectomy via transradial access for the treatment of peripheral artery disease (PAD) in lower extremity lesions.

According to a press release, the company’s low profile, 5Fr, Extended Length Diamondback 360 Peripheral Orbital Atherectomy System (OAS) and Extended Length Stealth 360 Peripheral OAS are the only atherectomy devices that allow radial access for the treatment of peripheral lesions.

National Primary Investigator for REACH PVI, Ankur Lodha, interventional cardiologist at the Cardiovascular Institute of the South in Lafayette, USA, enrolled the first patient.

Lodha said, “When endovascular intervention is necessary, PAD lesions are mostly treated through femoral artery access. However, many PAD patients could benefit from faster ambulation time post procedure that radial artery access offers. In addition, some patients may have comorbidities, such as obesity, that complicate or preclude femoral access.”

Lodha continued, “The benefits of radial access for percutaneous peripheral vascular interventions are well documented. We believe this study will demonstrate that many of these known benefits, such as low complication rates, high cost effectiveness, and short time to ambulation, can be achieved using orbital atherectomy to treat lower limb PAD lesions through radial access.”

Scott Ward, CSI chairman, president, and chief executive officer, said, “CSI continues to innovate and develop medical evidence to improve the care of patients suffering from PAD. The commercialisation of the Extended Length orbital atherectomy systems and our investment in REACH PVI both demonstrate our commitment to physicians and the patients they serve.”

About REACH PVI
REACH PVI is a prospective, observational, single-arm, multicentre post-market study that will enrol 50 patients at up to 10 sites across the USA. The purpose of this study is to prospectively evaluate acute clinical outcomes of orbital atherectomy via transradial access for treatment of peripheral artery disease (PAD) in lower extremity lesions. The study will include CSI orbital atherectomy devices FDA-cleared for treatment of PAD. All subjects will be followed post-procedure through the first standard of care follow-up visit (7–45 days post-procedure).

Source VascularNews

Duc Tin Clinic

Print Chia sẽ qua facebook bài: Cardiovascular Systems announces first patient enrolled in REACH PVI clinical study Chia sẽ qua google bài: Cardiovascular Systems announces first patient enrolled in REACH PVI clinical study Chia sẽ qua twitter bài: Cardiovascular Systems announces first patient enrolled in REACH PVI clinical study Chia sẽ qua MySpace bài: Cardiovascular Systems announces first patient enrolled in REACH PVI clinical study Chia sẽ qua LinkedIn bài: Cardiovascular Systems announces first patient enrolled in REACH PVI clinical study Chia sẽ qua stumbleupon bài: Cardiovascular Systems announces first patient enrolled in REACH PVI clinical study Chia sẽ qua icio bài: Cardiovascular Systems announces first patient enrolled in REACH PVI clinical study Chia sẽ qua digg bài: Cardiovascular Systems announces first patient enrolled in REACH PVI clinical study Chia sẽ qua yahoo bài: Cardiovascular Systems announces first patient enrolled in REACH PVI clinical study Chia sẽ qua yahoo bài: Cardiovascular Systems announces first patient enrolled in REACH PVI clinical study Chia sẽ qua yahoo bài: Cardiovascular Systems announces first patient enrolled in REACH PVI clinical study Chia sẽ qua yahoo bài: Cardiovascular Systems announces first patient enrolled in REACH PVI clinical study

Tin tức liên quan

CUSTOMER REVIEWS

  • I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

    I sincerely thank you !. Tel: 0938303275

  • Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

    Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

  • As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

  • The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

  • I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.

Search
Customer support

    Phone: (028) 3981 2678
    Mobile: 0903 839 878 - 0909 384 389

TOP